# Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

> **NCT02803437** · — · COMPLETED · sponsor: **Bayer** · enrollment: 334 (actual)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY 88-8223)

## Key facts

- **NCT ID:** NCT02803437
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-21
- **Primary completion:** 2022-01-06
- **Final completion:** 2024-12-18
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02803437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02803437, "Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02803437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*